Frontier Biotechnologies Inc. (SHA:688221)
22.22
-0.20 (-0.89%)
At close: Jul 30, 2025, 2:57 PM CST
Accolade Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2020 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2020 |
Operating Revenue | 129.44 | 125.76 | 110.42 | 83.4 | 40.47 | 46.37 | Upgrade |
Other Revenue | 3.71 | 3.71 | 3.83 | 1.34 | 0.03 | 0.25 | Upgrade |
133.15 | 129.47 | 114.25 | 84.74 | 40.5 | 46.62 | Upgrade | |
Revenue Growth (YoY) | 4.86% | 13.33% | 34.82% | 109.22% | -13.13% | 123.50% | Upgrade |
Cost of Revenue | 97.77 | 95.63 | 81.13 | 69.35 | 49.71 | 42.5 | Upgrade |
Gross Profit | 35.38 | 33.84 | 33.12 | 15.39 | -9.21 | 4.12 | Upgrade |
Selling, General & Admin | 174.99 | 171.16 | 159.52 | 135.04 | 136.81 | 109.4 | Upgrade |
Research & Development | 119.94 | 137.21 | 214.23 | 274.33 | 172.11 | 138.49 | Upgrade |
Other Operating Expenses | 6.96 | 4.6 | 3.17 | 2.98 | 1.98 | 1.48 | Upgrade |
Operating Expenses | 300.44 | 310.75 | 377.34 | 413.94 | 312.12 | 249.77 | Upgrade |
Operating Income | -265.06 | -276.9 | -344.22 | -398.56 | -321.33 | -245.65 | Upgrade |
Interest Expense | -10.65 | -10.36 | -8.47 | -4.75 | -1.53 | -1.36 | Upgrade |
Interest & Investment Income | 86.97 | 88.21 | 23.51 | 25.9 | 44.3 | 7.37 | Upgrade |
Currency Exchange Gain (Loss) | 0.15 | 0.15 | -3.58 | 0.68 | 0.09 | -0.62 | Upgrade |
Other Non Operating Income (Expenses) | -3.97 | -3.05 | -0.91 | -2.03 | -0.48 | -0.55 | Upgrade |
EBT Excluding Unusual Items | -192.56 | -201.95 | -333.66 | -378.75 | -278.96 | -240.81 | Upgrade |
Gain (Loss) on Sale of Investments | -1.32 | 0.08 | -1.06 | -0.25 | 0.72 | 1.27 | Upgrade |
Gain (Loss) on Sale of Assets | -0.02 | -0.03 | -3.08 | -0.01 | 0 | -0 | Upgrade |
Asset Writedown | -36.3 | -36.65 | -3.22 | - | - | - | Upgrade |
Other Unusual Items | 40.4 | 37.16 | 12.05 | 22.25 | 12.97 | 4.02 | Upgrade |
Pretax Income | -189.8 | -201.38 | -328.96 | -356.76 | -265.27 | -235.52 | Upgrade |
Earnings From Continuing Operations | -189.8 | -201.38 | -328.96 | -356.76 | -265.27 | -235.52 | Upgrade |
Minority Interest in Earnings | - | - | - | - | 5.21 | 4.79 | Upgrade |
Net Income | -189.8 | -201.38 | -328.96 | -356.76 | -260.06 | -230.73 | Upgrade |
Net Income to Common | -189.8 | -201.38 | -328.96 | -356.76 | -260.06 | -230.73 | Upgrade |
Shares Outstanding (Basic) | 372 | 373 | 374 | 364 | 361 | 288 | Upgrade |
Shares Outstanding (Diluted) | 372 | 373 | 374 | 364 | 361 | 288 | Upgrade |
Shares Change (YoY) | -0.01% | -0.24% | 2.69% | 0.79% | 25.23% | 9.40% | Upgrade |
EPS (Basic) | -0.51 | -0.54 | -0.88 | -0.98 | -0.72 | -0.80 | Upgrade |
EPS (Diluted) | -0.51 | -0.54 | -0.88 | -0.98 | -0.72 | -0.80 | Upgrade |
Free Cash Flow | -203.48 | -191.12 | -396.52 | -429.42 | -570.22 | -356.59 | Upgrade |
Free Cash Flow Per Share | -0.55 | -0.51 | -1.06 | -1.18 | -1.58 | -1.24 | Upgrade |
Gross Margin | 26.57% | 26.14% | 28.99% | 18.16% | -22.74% | 8.85% | Upgrade |
Operating Margin | -199.06% | -213.87% | -301.28% | -470.32% | -793.34% | -526.88% | Upgrade |
Profit Margin | -142.54% | -155.54% | -287.94% | -421.01% | -642.07% | -494.89% | Upgrade |
Free Cash Flow Margin | -152.82% | -147.61% | -347.07% | -506.74% | -1407.84% | -764.83% | Upgrade |
EBITDA | -249.99 | -256.28 | -301.34 | -352.29 | -283.37 | -207.46 | Upgrade |
EBITDA Margin | -187.75% | -197.94% | -263.76% | - | - | - | Upgrade |
D&A For EBITDA | 15.07 | 20.63 | 42.88 | 46.27 | 37.96 | 38.19 | Upgrade |
EBIT | -265.06 | -276.9 | -344.22 | -398.56 | -321.33 | -245.65 | Upgrade |
EBIT Margin | -199.06% | -213.87% | - | - | - | - | Upgrade |
Revenue as Reported | 133.15 | 129.47 | 114.25 | 84.74 | 40.5 | 46.62 | Upgrade |
Advertising Expenses | - | 0.52 | 0.31 | 0.09 | 1.13 | 0.81 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.